• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Dexcom Introduces Generative AI Platform for Glucose Biosensing

by Jasmine Pennic 12/17/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo. 

– The Stelo platform analyzes individual health data patterns to provide personalized insights and recommendations for improving metabolic health.

AI-Powered Personalized Guidance

The Dexcom GenAI platform leverages Google Cloud’s Vertex AI and Gemini models to analyze user data and generate personalized insights related to diet, exercise, and sleep. This technology enhances Dexcom’s existing Weekly Insights feature, offering users more tailored guidance and support in managing their health.

Stelo: The First GenAI-Enabled CGM

Stelo, Dexcom’s over-the-counter glucose biosensor, is the first product to integrate this GenAI technology. Users will now receive personalized tips, recommendations, and education within the Stelo app, empowering them to make informed decisions about their health.

Key Benefits of Dexcom’s GenAI Platform

  • Personalized Insights: Provides users with tailored guidance based on their individual health data patterns.
  • Improved Metabolic Health: Helps users understand the impact of lifestyle choices on their glucose levels and make informed decisions to improve their metabolic health.
  • Enhanced User Experience: Delivers personalized content and recommendations within the Stelo app, making it easier for users to manage their health.
  • Innovation in Glucose Biosensing: Positions Dexcom as a leader in the integration of AI with CGM technology.

Stelo Expansion Plans

Dexcom plans to expand its GenAI platform across its product portfolio, offering more personalized and insightful health management tools to its millions of users worldwide. This technology has the potential to revolutionize diabetes care and improve the lives of people with metabolic conditions.

“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualize their health information and make proactive, informed lifestyle decisions.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Continuous Glucose Monitoring (CGM), Dexcom, Diabetes Management, Generative AI

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |